It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Osteocytes are mechanosensitive bone cells, but little is known about their effects on tumor cells in response to mechanical stimulation. We treated breast cancer cells with osteocyte-derived conditioned medium (CM) and fluid flow-treated conditioned medium (FFCM) with 0.25 Pa and 1 Pa shear stress. Notably, CM and FFCM at 0.25 Pa induced the mesenchymal-to-epithelial transition (MET), but FFCM at 1 Pa induced the epithelial-to-mesenchymal transition (EMT). This suggested that the effects of fluid flow on conditioned media depend on flow intensity. Fluorescence resonance energy transfer (FRET)-based evaluation of Src activity and vinculin molecular force showed that osteopontin was involved in EMT and MET switching. A mouse model of tumor-induced osteolysis was tested using dynamic tibia loadings of 1, 2, and 5 N. The low 1 N loading suppressed tumor-induced osteolysis, but this beneficial effect was lost and reversed with loads at 2 and 5 N, respectively. Changing the loading intensities in vivo also led to changes in serum TGFβ levels and the composition of tumor-associated volatile organic compounds in the urine. Collectively, this study demonstrated the critical role of intensity-dependent mechanotransduction and osteopontin in tumor-osteocyte communication, indicating that a biophysical factor can tangibly alter the behaviors of tumor cells in the bone microenvironment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Harbin Medical University, Department of Pharmacology, School of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268); Indiana University Purdue University Indianapolis, Department of Biomedical Engineering, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
2 Indiana University Purdue University Indianapolis, Department of Biomedical Engineering, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
3 Indiana University Purdue University Indianapolis, Department of Biomedical Engineering, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919); Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China (GRID:grid.257413.6)
4 Indiana University Purdue University Indianapolis, Department of Physics, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
5 Oakland University, Department of Mechanical Engineering, Rochester, USA (GRID:grid.261277.7) (ISNI:0000 0001 2219 916X)
6 Indiana University Purdue University Indianapolis, Integrative Nanosystems Development Institute, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
7 Indiana University School of Medicine, Department of Anatomy and Cell Biology, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919); Indiana University School of Medicine, Indiana Center for Musculoskeletal Health, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
8 Indiana University School of Medicine, Department of Surgery, Simon Cancer Research Center, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
9 Harbin Medical University, Department of Pharmacology, School of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268)
10 Harbin Medical University, Department of Pharmacology, School of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268); Indiana University Purdue University Indianapolis, Department of Biomedical Engineering, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919); Oakland University, Department of Mechanical Engineering, Rochester, USA (GRID:grid.261277.7) (ISNI:0000 0001 2219 916X); Indiana University Purdue University Indianapolis, Integrative Nanosystems Development Institute, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919); Indiana University School of Medicine, Department of Anatomy and Cell Biology, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919); Indiana University School of Medicine, Indiana Center for Musculoskeletal Health, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)